Anavex Life Sciences Corp (AVXL)

[Investor2014]

Not very concise ramblings and thus hard to comment on specially.

Not sure how the author of the post can come to the conclusions that Anavex might have dropped AD.

I would just give that a pass and look for posts with considered arguments and by that I don’t mean we got this or possessing special understanding of the uniqueness of A2-73.

Anavex themselves do not understand anywhere near fully the MoA of A2-73, but they have planned and are executing current trials based on all they could learn from their’s and other’s pre- and clinical work to date.

As investors we have made our bets for the outcome of current trials. The AD P2b/3 trial will readout late 2022 no matter any ramblings.

Of course one should keep looking out for new approaches, Anavex isn’t and won’t be the only game in town.